KODAK-ICN RESEARCH VENTURE TO FOCUS ON DISCOVERY OF ANTIVIRAL, ANTI-AGING AGENTS
Executive Summary
KODAK-ICN RESEARCH VENTURE TO FOCUS ON DISCOVERY OF ANTIVIRAL, ANTI-AGING AGENTS, a recent press release announcing the formation of the joint research institute indicated. According to the release, the institute will "explore new biomedical compounds," dedicating "much of its research exclusively to preclinical studies of new antiviral and anti-aging substances." $45 mil. will be funneled into the formation and operation of the Nucleic Acid Research Institute by the two companies over a period of six years, the release said. When fully operational, the institute, which will be located at ICN's Costa Mesa, California facility, will employ more than 150 people. The institute will be headed by Waldon Jolley, Loma Linda University Medical Center, who will serve as president with additional responsibility for pharmacological research. Roland Robins, Brigham Young University Medical Center, will direct molecular research, and Robert Smith, UCLA, will supervise biomedical research. Commenting upon the importance of the research to Eastman Kodak, L. J. Thomas, senior VP and director of research for Kodak, said in the release: "We expect the Institute to build on ICN's pioneering work in the area of nucleic acid research, leading to specific substances with practical applications." The venture with ICN represents the latest step in Kodak's involvement in the health care field. Historically, the company has provided the industry with radiographic films and screens. Last February, Kodak established a biotechnology unit to expand its interests and capabilities in the biotechnology area ("The Pink Sheet" Feb. 25, T&G-1). ICN has one product in the pipeline, Virazole (ribavirin), with an NDA pending for the treatment of respiratory syncytial virus.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth